Related Experiment Videos
Abstract:
Fosfomycin is a relatively new antibiotic drug, deriving from streptomyces species. Its special chemical structure and small molecular size provide a very good diffusion into tissues like bone, fascia and wound exudates as well. In a clinical study Fosfomycin was given to 26 patients with infections mainly of the middle ear and mastoid as well as other ENT-infections. Clinical success, laboratory investigations and bacteriology are described in detail. The drug proved to be of special value in the treatment of chronic purulent otitis, purulent or chronic secreting tympanoplasties or other postoperative middle-ear affections when caused by penicillin-resistant staphylococci, proteus-species and pseudomonas aeruginosa. In the other cases treatment results were good corresponding to the bactericidal spectrum of Fosfomycin. There was one treatment failure in our series, but no reverse reaction at all.
Insights
Fosfomycin effectively treats various ENT infections, particularly chronic otitis and post-operative ear conditions caused by resistant bacteria. This antibiotic shows good diffusion into tissues with no adverse reactions observed in a clinical study.
Area of Science:
- Pharmacology
- Microbiology
- Otolaryngology
Background:
- Fosfomycin, an antibiotic from Streptomyces species, possesses a unique chemical structure and small molecular size.
- Its properties allow excellent diffusion into diverse tissues, including bone, fascia, and wound exudates.
Observation:
- A clinical study evaluated Fosfomycin in 26 patients with middle ear, mastoid, and other ENT infections.
- Detailed clinical success, laboratory, and bacteriology data were collected and analyzed.
Findings:
- Fosfomycin demonstrated significant value in treating chronic purulent otitis and post-operative ear infections caused by penicillin-resistant Staphylococcus, Proteus, and Pseudomonas aeruginosa.
- Treatment results in other cases were favorable, aligning with Fosfomycin's bactericidal spectrum.
- One case of treatment failure was noted, with no adverse reactions reported.
Implications:
- Fosfomycin is a promising therapeutic option for challenging ENT infections, especially those involving multidrug-resistant bacteria.
- Its favorable pharmacokinetic profile and safety suggest potential for broader clinical application in treating localized infections.
- Further research may explore Fosfomycin's efficacy in other infection types and patient populations.